Manufacturing, Cell Therapies

Cellular Origins Collaborates with ScaleReady for Cell and Gene Therapies

May 11, 2023

The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.

Arranta Bio Signs Contract with MIT for Rapid mRNA Manufacturing Therapeutics

May 03, 2023

mRNA therapeutics are being researched to support the fight against rare diseases, infectious viruses, and cancers.

Challenges of Expanding CAR-T Cell Therapy into Solid Tumors

May 03, 2023

The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.

Ginkgo Bioworks Acquires AAV Capsid Technology and Forms Partnership for Next-Gen CAR-T Cell Therapies

April 14, 2023

Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.

Forecyte Bio Opens New GMP Facility in Shanghai

April 12, 2023

Forecyte Bio has opened a new GMP facility in Shanghai just two months after its sister site in the United States.

Sartorius to Acquire Polyplus in $2.6 Billion Deal

April 05, 2023

Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.

High-titre Vector Producing Cells

April 02, 2023

Decreasing vein to vein time saves lives.

TrakCel and Lonza Reach Integration Milestone to Combine Cell and Gene Therapy Manufacturing, Orchestration Solutions

March 22, 2023

The combined solutions are currently available on the market.

The Center for Breakthrough Medicines Announces Plasmid Manufacturing Service

February 07, 2023

CBM’s plasmid manufacturing offering is designed to provide phase-appropriate plasmids on demand for companies working on cell and gene therapies.

Technology for In Vivo CAR T-cell Therapy Advances

February 02, 2023

In vivo CAR-T gene therapies could resolve challenges faced by autologous and allogeneic treatments.